Isatuximab Addition to Standard Therapy Reduces Disease Progression in Myeloma
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on December 11th, 2024
|
Multiple myeloma is currently treated with a triple combination of bortezomib, a proteasome inhibitor, lenalidomide, a ligase-modulating agent, and the anti-inflammatory glucocorticoid dexamethasone. Since CD38 is highly expressed on the surface of multiple myeloma tumor cells, Sanofi sponsored a study to explore the potential benefits of adding the anti-CD38 antibody isatuximab to the existing treatment regimen.
The phase 3 clinical trial involved 446 participants diagnosed with myeloma, with approximately two-thirds having IgG myeloma, 20% having IgA disease, and 10% experiencing mutations in the light chain. The patients were randomly assigned to receive either the standard triplet therapy or the same regimen with the addition of isatuximab. Isatuximab was administered intravenously at a dose of 10 mg per kilogram of body weight once a week, with the frequency reduced to every other week after the first four doses. After a median follow-up of around 60 months, the researchers found that adding isatuximab to the combination of bortezomib, lenalidomide, and dexamethasone reduced the risk of disease progression or death by 40%. Furthermore, the addition of isatuximab significantly increased the likelihood of achieving partial or complete tumor shrinkage. The researchers noted that isatuximab usage increased the frequency of neutropenia and leukopenia; coincidentally, this increased the risk of COVID-19 related death.
The phase 3 clinical trial involved 446 participants diagnosed with myeloma, with approximately two-thirds having IgG myeloma, 20% having IgA disease, and 10% experiencing mutations in the light chain. The patients were randomly assigned to receive either the standard triplet therapy or the same regimen with the addition of isatuximab. Isatuximab was administered intravenously at a dose of 10 mg per kilogram of body weight once a week, with the frequency reduced to every other week after the first four doses. After a median follow-up of around 60 months, the researchers found that adding isatuximab to the combination of bortezomib, lenalidomide, and dexamethasone reduced the risk of disease progression or death by 40%. Furthermore, the addition of isatuximab significantly increased the likelihood of achieving partial or complete tumor shrinkage. The researchers noted that isatuximab usage increased the frequency of neutropenia and leukopenia; coincidentally, this increased the risk of COVID-19 related death.